- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2020
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2020
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2020 | Daily Highlights
HCQ and arrhythmia
HYDROXYCHLOROQUINE USE WAS NOT ASSOCIATED WITH QTC LENGTH IN A LARGE COHORT OF SLE AND RA PATIENTS
Abstract: 0431
Authors: Park E. et al.
Key content:
Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE). However, its use in the treatment of COVID-19 has raised concerns for the possibility of QTc prolongation and development of arrhythmia. This study explored the association between QTc length and HCQ in a total of 681 RA and SLE patients and demonstrates that QTc length does not significantly differ in HCQ users compared with non-HCQ users even while adjusting for potential clinical confounders. HCQ use was not associated with a prolonged QTc (>440 ms) nor was HCQ use a significant predictor of QTc length.
Relevance:
The use of HCQ in doses used for RA and SLE treatment is not associated with an increased risk of arrhythmia.

Zusammenfassung und Kommentar von:
Prof. Dr. Ulrich Walker
Basel